PathoQuest announced the appointment of Dr. Laurent Lafferrere as company COO. Dr. Laurent Lafferrère has over 20 years of experience in the pharmaceutical industry, in CMC divisions, including 10 years of experience in executive management.
Transgene chooses PathoQuest innovative NGS-based safety release test for TG4050 phase I clinical trial targeting patients with head-neck and ovarian cancers and for Invir.IO™ a platform for recombinant viral vector manufacturing.
Transgene is a French biotechnology company focused on designing and developing next generation immunotherapeutics. In these phase 1 trials with 85 patients, Transgene has chosen PathoQuest next generation sequencing (NGS) solutions for its fast and cost-effective viral safety testing approach of the product.
PathoQuest CEO Jean-François Brepson discusses “NGS and New Frontiers in Infectious Disease” during new Illumina Genomics podcast
The Illumina Genomics Podcast (Episode 53) has Jean-François Brepson CEO of PathoQuest discusses the company’s vision of the impact of NGS on the diagnosis of infectious disease with the development of iDTECT™ blood.
100brevets.tech – Inventors of the French Tech Awards – has ranked PathoQuest as the 32nd most inventive start-up based in France and the 7th ranked MedTech company.
PathoQuest is a member of MabDesign, a membership organization dedicated to the creation of a unique environment that allows the economic development and growth of the French industrial sector in the field of therapeutic antibody and immunotherapy.
PathoQuest announced that it has received Propel Certification from Illumina after successfully completing the requirements for achieving this recognition. This included demonstrating the ability to produce high-quality data on the NexSeq System following a streamlined and rigorous process.